Novel organometallic compounds for cancer treatment

Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.

dc.contributor.author	Zhanbossinova, A.
dc.contributor.author	Yespolayeva, S.
dc.contributor.author	Khamitova, G.
dc.contributor.author	Negmetzhanov, B.
dc.contributor.author	Alibek, K.
dc.contributor.author	Adilov, S.
dc.date.accessioned	2015-10-28T09:19:19Z
dc.date.available	2015-10-28T09:19:19Z
dc.date.issued	2013
dc.identifier.uri	http://nur.nu.edu.kz/handle/123456789/558
dc.description.abstract	Incorporating indole, resorcinol, and porphyrin derivatives into ferrocene and ruthenium complexes could improve their anticancer activity. These compounds are furnished with functional groups which are expected to induce programmed cell death and show high selectivity to cancer cells. Currently, they are at the stage of in vitro testing for anticancer activity.	ru_RU
dc.language.iso	en	ru_RU
dc.publisher	Nazarbayev University	ru_RU
dc.subject	first research week	ru_RU
dc.subject	cancer treatment	ru_RU
dc.subject	anticancer activity	ru_RU
dc.title	Novel organometallic compounds for cancer treatment	ru_RU
dc.type	Abstract	ru_RU